Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
USP6
REST API REST API
Homo sapiens
USP6 is differentially expressed in 271 experiments: 127 organism parts: lung, testis, ... (125 more);, 165 disease states: normal, healthy, ... (163 more);, 82 cell types 389 cell lines 27 compound treatments and 64 other conditions.
Synonyms Tre2, Tre-2, HRP1, TRE17
Orthologs USP6 (Danio rerio)   F6PJ70_CIOIN (Ciona intestinalis)   UBP12 (Saccharomyces cerevisiae)   CG8334 (Drosophila melanogaster)   usp32 (Xenopus laevis)   (Compare orthologs)
Gene Ontology Term plasma membrane, protein binding, cytoplasm, intracellular, ubiquitin thiolesterase activity, lysosome, peptidase activity, nucleic acid binding, ubiquitin-specific protease activity, recycling endosome, calmodulin binding, Rab GTPase activator activity, protein modification process, cysteine-type endopeptidase activity, protein deubiquitination, regulation of Rab GTPase activity, ubiquitin-dependent protein catabolic process, regulation of vesicle-mediated transport
InterPro Term Peptidase_C19, RabGAP/TBC_dom
UniProt Accession P35125, Q6U210, E7EUU2
Search EB-eye ENSG00000129204
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-17189, E-GEOD-803, E-AFMX-5, E-GEOD-6573, E-MEXP-1251, ... (23 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-3860, E-GEOD-5258, E-GEOD-19639, E-GEOD-2450, ... (35 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-19639, E-GEOD-3529, E-GEOD-20081, E-GEOD-5823
AGS
2
E-GEOD-15460, E-MTAB-37
BT-474
2
E-GEOD-5823, E-GEOD-3529
K562
2
E-MTAB-37, E-GEOD-24147
LNCaP
2
E-GEOD-14990, E-GEOD-14464
BT474
1
2
E-MEXP-440, E-MTAB-37, E-MTAB-62
383 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, E-MEXP-66, ... (43 experiments)

Factor Value U/D Experiments
dendritic cell
2
E-GEOD-3982, E-MEXP-2019
CD71+ early erythroid
2
E-AFMX-5, E-TABM-145
memory B cell
2
E-TABM-702, E-MEXP-2360
culture-derived megakaryocytes
1
E-MEXP-70
leydig cell
1
E-MTAB-25
CD8+ T cell
1
E-GEOD-6740
76 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-MEXP-1121, E-TABM-15, ... (53 experiments)

Factor Value U/D Experiments
uterine fibroid
2
E-MTAB-62, E-GEOD-7307
acute lymphoblastic leukemia
2
E-MTAB-37, E-MTAB-62
esophageal carcinoma
1
E-MTAB-37
precursor T lymphoblastic leukemia
1
E-MTAB-62
medulloblastoma
1
E-MTAB-37
carcinoma in situ, bladder tumor
1
E-MTAB-62
159 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-5741, E-TABM-868, E-GEOD-5099, E-MEXP-1958, ... (20 experiments)

Factor Value U/D Experiments
ethanol
2
E-MEXP-2241, E-MEXP-1014
lipopolysaccharide
2
E-MEXP-1958, E-TABM-868
unknown
1
E-GEOD-7307
1mM GDC-0941
1
1
E-GEOD-20719
TTA
1
E-MEXP-2590
AMP
1
1
E-MEXP-2285
21 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519


Biosource provider
studied in E-TABM-325, E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-MEXP-1251, E-GEOD-19246, E-GEOD-21374, ... (10 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-MEXP-2359, E-GEOD-6236, E-GEOD-2666, E-GEOD-4667, ... (6 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-22541, E-GEOD-22148, E-MEXP-2280, ... (10 experiments)

Environmental stress
studied in E-GEOD-1643

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-21589, E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, ... (10 experiments)

Genotype
studied in E-GEOD-2466, E-GEOD-17476, E-MEXP-421, E-TABM-321, E-TABM-868, ... (10 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681, E-MEXP-2657, E-GEOD-12773, E-TABM-127, ... (11 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653

Individual
studied in E-TABM-325, E-MTAB-197, E-MEXP-2069, E-GEOD-1926, E-MEXP-1648, ... (38 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-12254, E-GEOD-980

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Material type
studied in E-MEXP-455, E-MEXP-958, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-AFMX-1, E-TABM-84

Organism status
studied in E-GEOD-19188

Phenotype
studied in E-GEOD-19703, E-GEOD-22309, E-GEOD-21750, E-GEOD-1657, E-GEOD-17636, ... (7 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-19445, E-GEOD-19246

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-10797, E-GEOD-18791

RNAi
studied in E-MEXP-2115, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, E-MEXP-2759 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-MEXP-70, E-GEOD-17400

Sex
studied in E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-4922, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Test result
studied in E-GEOD-1926, E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-21909, E-GEOD-19246, E-GEOD-13818, ... (6 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 99 146
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.258 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM